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ABSTRACT
Objective: Advance care planning (ACP) clarifies
goals for future care if a patient becomes unable to
communicate their own preferences. However, ACP
uptake is low, with discussions often occurring late.
This study assessed whether a systematic nurse-led
ACP intervention increases ACP in patients with
advanced respiratory disease.
Design: A multicentre open-label randomised
controlled trial with preference arm.
Setting: Metropolitan teaching hospital and a rural
healthcare network.
Participants: 149 participants with respiratory
malignancy, chronic obstructive pulmonary disease or
interstitial lung disease.
Intervention: Nurse facilitators offered facilitated ACP
discussions, prompted further discussions with
doctors and loved ones, and assisted participants to
appoint a substitute medical decision-maker (SDM)
and complete an advance directive (AD).
Outcome measures: The primary measure was
formal (AD or SDM) or informal (discussion with
doctor) ACP uptake assessed by self-report (6 months)
and medical notes audit. Secondary measures were the
factors predicting baseline readiness to undertake ACP,
and factors predicting postintervention ACP uptake in
the intervention arm.
Results: At 6 months, formal ACP uptake was
significantly higher ( p<0.001) in the intervention arm
(54/106, 51%), compared with usual care (6/43, 14%).
ACP discussions with doctors were also significantly
higher ( p<0.005) in the intervention arm (76/106,
72%) compared with usual care (20/43, 47%). Those
with a strong preference for the intervention were more
likely to complete formal ACP documents than those
randomly allocated. Increased symptom burden and
preference for the intervention predicted later ACP
uptake. Social support was positively associated with
ACP discussion with loved ones, but negatively
associated with discussion with doctors.
Conclusions: Nurse-led facilitated ACP is acceptable
to patients with advanced respiratory disease and
effective in increasing ACP discussions and completion

Strengths and limitations of this study
▪ This randomised controlled trial includes a
patient preference arm, to more closely match
the real-world clinical environment.
▪ Longitudinal follow-up enables assessment of
multiple aspects of advance care planning uptake
among a specific patient cohort at high risk of
mortality.
▪ A higher than expected number of patients who
strongly preferred to receive the intervention
means the study arms are unbalanced.
▪ Patient attrition across the follow-up period and
self-selection associated with the use of a preference arm complicate the interpretation of study
data.
▪ A detailed description of characteristics associated
with the facilitated advance care planning intervention provides implications for practitioners.
of formal documents. Awareness of symptom burden,
readiness to engage in ACP and relevant psychosocial
factors may facilitate effective tailoring of ACP
interventions and achieve greater uptake.
Trial registration number: ACTRN12614000255684.

BACKGROUND
Advance care planning (ACP) is an ongoing
process of discussion between patients,
family, carers and health professionals aimed
at clarifying goals for future care and facilitating decision-making in situations when a
patient is unable to make decisions or communicate their own preferences.1 While ACP
has traditionally been understood and measured in terms of the completion of a formal
advance directive (AD) to specify preferences
for medical treatments or nomination of a
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substitute healthcare decision-maker (SDM), there is
growing awareness that such approaches do not capture
the full breadth of the planning and discussion
involved.2 3
Recent systematic reviews have supported the efﬁcacy
of ACP interventions,4 5 particularly those including
facilitated communication approaches in addition to
written directives.4 ACP is associated with positive outcomes in end-of-life care including reduced psychological morbidity among bereaved family members,
lower likelihood of dying in hospital and higher likelihood of planned hospice admission.3 6
Patients with severe respiratory disease, such as lung
cancer or chronic obstructive pulmonary disease
(COPD), have been identiﬁed as a group for whom ACP
is particularly relevant,7–9 as they experience heavy
symptom burden with a marked impact on quality of life
and care needs.10 11 Prognosis among these patients can
be poor; the 1-year mortality rate in metastatic non-small
cell lung cancer is over 70%12 and is over 20% among
patients hospitalised for acute exacerbation of COPD.13
While malignant respiratory disease has a somewhat predictable illness trajectory, COPD is characterised by signiﬁcant ﬂuctuation, in which periods of stability or
gradual decline are interspersed with acute exacerbations, any of which may be fatal.11 A study of patients
with advanced lung cancer and end-stage COPD showed
that while both groups expressed strong preferences for
comfort-focused care, those with COPD were signiﬁcantly more likely to receive invasive therapies.14
Despite this identiﬁcation of potential beneﬁt, ACP rates
remain low among patients with severe respiratory
disease.15 16 Patient-related barriers include a lack of information about their condition,17 18 a belief that clinicians
will initiate ACP discussion ‘when the time is right’,19 and
in some cases, a preference to avoid discussion about ACP
and end-of-life care.8 20 Patients with COPD in particular
are often unclear about their prognosis, unaware of their
likely illness trajectory and not informed about the types
of healthcare decisions they may face in the future.15 17 18
Doctors also report a range of barriers to ACP discussion
including lack of time,21 concern about upsetting
patients22 and prognostic uncertainty.23 Previous research
has established the relevance and effectiveness of nurses
in ACP facilitation, in community and hospital settings.6 24
Uptake of ACP can be usefully conceptualised as a
process, with modiﬁed stage-based models of health
behaviour change which describe patient ‘readiness’ (ie,
precontemplation, contemplation, preparation, action/
maintenance) to engage in the various aspects of ACP
including discussions with loved ones, discussions with
doctors and completion of formal documents.25 26
Validated interview and survey tools enable nuanced longitudinal measurement of psychological stages of ‘readiness’ over time, as opposed to measures focusing solely
on ‘completion’.2 27 28 This construct of ‘readiness’ to
undertake ACP has been shown to be associated with
illness-related experiences,8 29 experiences with
2

end-of-life care among others,29 30 social support6 24 and
proactive intervention by clinicians.26
The primary research question addressed in this
paper is whether a systematic nurse-led, facilitated ACP
intervention is effective in increasing ACP readiness and
uptake among patients with advanced respiratory
disease. The secondary aims are to (1) identify patient
factors associated with ACP readiness at baseline, and
(2) identify patient and contextual factors associated
with ACP uptake among those who were assigned to
receive the facilitated ACP intervention.
METHODS
Study design
This study was a multicentre open-label randomised controlled trial of nurse-led facilitated ACP with a preference
arm31 and a 2:1 randomisation protocol in favour of the
intervention. The preference arm enabled participants
with strong preferences (to either receive or avoid the
intervention) to be assigned to their preferred group.
Study setting
The study was implemented in a metropolitan and a
rural setting in Western Australia (WA). The metropolitan setting was a tertiary hospital respiratory department. The rural setting, ∼400 km away, consisted of
general practice (GP) clinics, residential aged care facilities (RACF) and the local regional hospital in a town of
∼30 000 people.
Participant eligibility criteria
Patients were eligible for the study if they were diagnosed
with a chronic, severe respiratory disease (lung cancer,
mesothelioma, malignant pleural effusion, COPD or
interstitial lung disease); fulﬁlled one or more of the
general or disease-speciﬁc criteria predicting ‘high risk’
of death, based on the Gold Standards Framework32
(table 1); were receiving treatment in one of the study settings; and were over 18 years of age. Patients were
excluded if they lacked capacity to consent; did not speak
English; had previously completed a formal AD (but not
excluding those who had previously nominated an SDM);
were on an ‘end-of-life’ pathway or otherwise expected to
die in the next 48 hours.
Recruitment and randomisation
In the metropolitan setting, potential participants were
identiﬁed through department database searches, clinic
letter reviews and direct referrals by ward staff. In the
rural setting, potential participants were identiﬁed
through GP database searches, direct referrals from participating GP clinics, regular meetings with RACF coordinators and attendance at clinical meetings in the
regional hospital. The nurse ACP facilitator conﬁrmed
the eligibility of each patient with their primary treating
doctor, and sought the doctor’s permission prior to
approaching them and explaining the study.
Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415
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Table 1 High-risk criteria for patient inclusion. Eligible patients were diagnosed with an eligible respiratory disease, and met
one or more of any of the general indicators or disease-specific triggers, or a ‘no’ in answer to the ‘surprise question’
General indicators:
1.
2.
3.
4.
5.
6.

WHO/ECOG performance status of 3 or greater33
Unstable and/or deteriorating symptom burden
Decreasing response to treatments
Weight loss >10% in past 6 months
Serum albumin <25 g/L
Repeated unplanned hospital admission(s) for a respiratory symptom

Disease-specific triggers
Idiopathic pulmonary fibrosis:
Malignant respiratory disease:
COPD:
1. Decline of >10% FVC in
1. Any metastatic disease (advanced lung
1. Severe disease on spirometry (FEV1
6 months
cancer; advanced mesothelioma, any
<25% predicted)
proven malignant pleural effusion)
2. Recurrent hospital admissions (3 or
2. Declining performance status with severe
more in a 12-month period)
respiratory disease of any cause (ie, ECOG
3. Fulfils LTOT criteria
3 or greater in BOTH of two assessments,
4. MRC grade shortness of breath 4–5
conducted more than 48 hours apart)
5. Right heart failure
6. 6 weeks or more of systemic steroids in
past 6 months
7. Respiratory failure within the past
12 months requiring intensive care unit
admission or non-invasive ventilation
The surprise question:
Ask the primary treating doctor responsible for the patient’s care: ‘Would you be surprised if the patient were to die in the next
few months, weeks or days?’34
COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; LTOT, long-term oxygen therapy; MRC, Medical Research Council.

During the recruitment process, potential participants
were informed that as part of participation they may be
invited to discuss the type of medical care they would want
if they were unable to make decisions and/or communicate their wishes, including discussion about life-sustaining
treatments and end-of-life care. Those who consented to
the study and expressed a strong preference to receive, or
avoid, the facilitated ACP intervention were assigned to
their preferred intervention or usual care (control) arm,
respectively (called ‘Pref-ACP’ and ‘Pref-CON’).
Patients willing to be randomised were allocated
(called ‘Rand-ACP’ and ‘Rand-CON’) following consent
(see ﬁgure 1). SFE generated the random allocation
sequence in permuted blocks (N=21 per block), and
ﬁlled opaque, sealed envelopes with allocation slips. The
nurse facilitators asked each patient to select an envelope; both the nurse and patient were blinded to the
contents of the envelope prior to allocation. The allocation protocol initially employed a 2:1 randomisation
schedule. Following planned preliminary analysis and
observation of a higher than expected number of
patients expressing a strong preference for the intervention, this was revised to a 1:1 schedule (ethics committee
approval 12/2/2015), and recruitment was ended on
16/9/2015 due to reporting deadlines.
A target sample size of n=150 in each study setting
was based on a power calculation of 0.80, assuming a
Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415

log-normal distribution, and a 75% ratio of geometric
mean levels of ACP uptake between the usual care and
intervention arms.
Intervention: nurse-led facilitated ACP
The intervention provided nurse-led support to the participant, their family and their doctors to facilitate
engagement in ACP. A nurse facilitator was employed in
each setting to coordinate recruitment, deliver the intervention and collect surveys. Both were senior nurses with
extensive experience in communication with severely ill
patients. Intervention ﬁdelity was maintained across the
study settings by research team participation in a full-day
workshop delivered by an external consultant (using
evidence-based resources adapted with permission from
Respecting Patient Choices), a detailed study protocol
and regular meetings between the nurse facilitators and
the broader research team.
Participants assigned to the intervention were offered
an appointment with the nurse facilitator to discuss
their illness and prognosis, reﬂect on goals and values
for future medical care, talk about these with loved ones
and doctors, appoint an SDM, and/or formally document future treatment preferences in an AD.
In the metropolitan setting, the intervention typically
occurred in an outpatient clinic, and in the rural setting
this occurred in a GP room or in the participant’s
3
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Inclusion of the notes audit meant that ACP uptake
could be assessed for patients who had died or were lost
to follow-up prior to the 6-month follow-up surveys.
Medical notes audit was undertaken by the nurse facilitators using a structured audit tool.36 The sections of the
notes containing evidence of ACP uptake were scanned
and de-identiﬁed, to allow inspection by the analysts in
the research team (CS and SFE), who ensured that
documentation met the deﬁnition of ACP uptake.
For the primary outcome, ‘formal ACP uptake’ was
deﬁned as self-reported completion of a written AD (in
WA, this means an ‘Advance Health Directive’37 or a ‘My
Advance Care Plan’ form38), or written nomination of
an SDM (an ‘Enduring Power of Guardianship’39) at
6-month follow-up. For those who died or were lost to
follow-up prior to the 6-month survey, the self-report
data were supplemented by medical notes audit.
‘Informal ACP uptake’ was deﬁned as self-reported completion of at least one discussion about life-sustaining
treatments with doctors at 6-month follow-up, or documentation of ACP conversations found at notes audit.
Figure 1 Schematic diagram of participants approached,
consented and recruited to trial. ACP, advance care planning;
LCP, Liverpool Care Pathway.

home. Follow-up meetings with the nurse facilitator were
scheduled opportunistically, or by participant request.
The date, length (minutes), location, people present
and domains covered in each ACP discussion were
recorded on a checklist. Any formal ACP documentation
completed as part of the intervention was distributed to
the participant, their family carer/s, regular GP and
medical records department of the relevant hospital.
Measures
Participant age, gender, country of birth, religion and
highest level of education attained were recorded at
baseline. Each participant’s primary respiratory diagnosis, secondary respiratory diagnoses (where applicable),
Medical Research Council (MRC) breathlessness scale
grading and eligibility for long-term oxygen therapy
(LTOT) were obtained from medical notes during
screening for eligibility.35
Primary outcome: ACP uptake
Two approaches were taken to measuring ACP uptake.
First, participant interviews, administered at baseline, 3
and 6 months postconsent, employed a validated survey
tool to assess stage of readiness to engage in relevant
aspects of ACP: (1) completion of a written AD, (2)
documentation of an SDM, (3) discussion about lifesustaining treatments with loved ones and (4) discussion
about life-sustaining treatments with doctors.27 Second,
at 12 months after consent, time of death or study end
point (whichever occurred ﬁrst), participants’ medical
notes were audited from the time of consent to assess
the presence of ‘formal’ or ‘informal’ documentation of
patient preferences regarding future medical care.
4

Secondary measures
Participant self-reported health-related quality of life
(HRQOL), satisfaction with healthcare and social
support was measured at baseline. The EuroQol 5
Dimensions 5 Level Survey (EQ-5D-5L) scores HRQOL
on ﬁve dimensions (mobility, ability to self-care, ability
to undertake usual activities, pain and anxiety/depression) and a global HRQOL visual analogue scale (VAS)
scored continuously from 1 to 100. Index values for the
EQ-5D-5L were calculated with algorithms derived from
the ‘cross-walk’ mapping to existing EQ-5D-3L data sets,
using UK population data (in the absence of Australian
validation data).40
Satisfaction with healthcare was assessed using the
Patient Satisfaction Index (PSI), a validated 23-item
instrument, summated to give a global score reﬂecting
satisfaction with level of healthcare received, involvement
in healthcare decision-making and interactions with
healthcare professionals over the previous 3 months.41
Social support was measured by summating the
seven-item ENRICHD tool, which assesses instrumental
and emotional aspects of support, rather than the size of
the social network.42 Owing to the small amount of
missing data (0.7% for ENRICHD, 1.7% for PSI) and unidimensional scale characteristics, missing data points
were imputed from each participant’s mean score.43
Data analysis
Variables collected at baseline were assessed for matching across trial arms, with χ2 tests for categorical variables and one-way analysis of variance for continuous
variables. The primary outcome was assessed by Fisher’s
exact test and relative risk estimation of ACP uptake with
assignment (facilitated ACP vs usual care), preference
(strong preference for ACP vs ambivalent) and time
(baseline vs 6-month follow-up).
Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415
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Secondary exploratory analyses determined the factors
predicting ‘baseline ACP readiness’ among all patients,
and ‘postintervention formal ACP uptake’ and ‘postintervention informal ACP uptake’, among patients
assigned to receive the facilitated ACP intervention.
Signiﬁcant predictors were assessed with separate multivariate logistic regression models, using type III sums of
squares estimation, with forced entry and stepwise, backwards elimination of non-signiﬁcant variables ( p>0.2).
Initial models included demographic variables (gender,
age, country of birth, level of education), baseline survey
scores (EQ-5D-5L index scores and global VAS, satisfaction with healthcare, social support) and clinical variables (malignant disease, COPD, MRC breathlessness
scale and LTOT eligibility). In addition, analysis of ‘postintervention formal ACP uptake’ and ‘postintervention
informal ACP uptake’ included baseline ACP readiness,
assigned group, hospital admission during the follow-up
period, number of ACP discussions undertaken with the
nurse facilitator and presence of a family member or
carer in an ACP discussion as potential predictors.
The study was registered with the Australia and New
Zealand Clinical Trials Registry (ACTRN12614000255684,
Registration date: 10/3/2014).

Facilitated ACP intervention
The characteristics of the facilitated ACP intervention
for the 106 participants assigned to the intervention are
presented in table 3. In the metropolitan setting, 31
(64%) participants had at least one discussion with the
nurse facilitator; these were predominantly in outpatient
clinics (94%) and lasted an average of 55 min
(SD=25.0). In the rural setting, 58 (100%) participants
had at least one discussion with the nurse facilitator;
these were typically home visits (60%) and lasted an
average of 25 min (SD=16.6), with a higher percentage
of rural participants (69% vs 4%, p<0.001) participating
in two or more discussions.

RESULTS
Over a 15-month period, 266 patients were screened as
being potentially eligible across both sites, of whom 215
were conﬁrmed eligible and invited to participate. Of
these participants, 150 consented, with one withdrawing
before assignment. Eighty-two patients had a strong preference for a particular study arm (ACP or usual care)
while 67 were ambivalent and hence randomly allocated
to either the intervention or usual care (see ﬁgure 1).
Owing to the lower than expected recruitment rates,
data were combined across sites to maintain adequate
study power.
Demographics and clinical proﬁle at baseline are presented in table 2. The sample was predominantly male
(94/149, 63%), with a moderate-to-low educational
status. COPD was the most common respiratory diagnosis (95/149, 64%) and 54 (36%) participants were
deceased at 12-month follow-up. Baseline rates of ACP
discussion with loved ones or doctors did not vary signiﬁcantly across the different diagnosis groups.
Among those who were randomly allocated, there
were no signiﬁcant differences in primary respiratory
diagnoses or measures of disease severity, and most measures of baseline ACP readiness showed no signiﬁcant
differences across study arms. The exception was that
those in the Rand-CON group reported higher baseline
rates of discussion with their doctor about life-sustaining
treatments (9/22, 41%) compared with those in the
Rand-ACP group (8/45, 18%, p<0.05).
Compared with those in the Rand-ACP group, participants in the Pref-ACP group had a lower HRQOL index
(0.43 vs 0.55, p<0.05), lower rates of living with a married

ACP readiness and uptake
The number of participants with formal or informal
ACP uptake at baseline and follow-up is presented in
table 4. The number of participants who had contemplated or completed different aspects of ACP at baseline
and follow-up (3 and 6 months) is presented in online
supplementary appendix 1.
For the primary outcome, formal ACP uptake over time
(baseline vs 6-month follow-up) found signiﬁcant effects
of assignment and preference. There was an increased
likelihood of having ACP uptake at 6-month follow-up
(relative risk (RR) 3.65, 95% CI 1.70 to 7.85) among
those assigned to receive the intervention (54/106,
50.9%), compared with those assigned to usual care
(6/43, 14.0%). There was also increased ACP uptake at
6-month follow-up (RR 2.58, 95% CI 1.55 to 4.31) among
those with a strong preference for the intervention
(42/61, 68.9%) compared with those allocated randomly
to receive the intervention (12/45, 26.7%). These results
were conﬁrmed with logistic regression analysis allowing
an interaction between preference and assignment.
Among those assigned to ACP intervention, those with a
strong preference (Pref-ACP) had an OR of 6.1 (95%
CI 2.6 to 14.3) of ACP uptake, compared with those
allocated randomly (Rand-ACP). There was no difference
between those allocated randomly to ACP and those
assigned to usual care (OR 1.6, 95% CI 0.5 to 5.8).
Informal ACP uptake was signiﬁcantly higher at 6-month
follow-up (76/106, 71.7%) compared with baseline (33/
106, 31.1%, p<0.001) for those assigned to the intervention, while those assigned to usual care did not show a signiﬁcant difference in uptake over time (12/43, 27.9% vs
20/43, 46.5%, NS).

Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415

or de facto partner (28/61, 46% in Pref-ACP vs 33/45,
73% in Rand-ACP, p<0.01), higher rates of completing
secondary school (27/61, 44% in Pref-ACP vs 8/45, 18%
in Rand-ACP, p<0.01), greater numbers reporting limitations in their ability to self-care (34/61, 56% in Pref-ACP
vs 13/45, 29% in Rand-ACP, p<0.01), higher rates of
anxiety or depression (29/61, 48% in Pref-ACP vs 10/45,
22% in Rand-ACP, p<0.01) and were more likely to be
recruited in the metropolitan setting (35/61, 57% in
Pref-ACP vs 13/45, 29% in Rand-ACP, p<0.01).
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Table 2 Participant characteristics by assigned group (percentages expressed by column)
Intervention
Pref-ACP
Rand-ACP
(N=61)
(N=45)
Recruitment site
N (%) metropolitan hospital
N (%) rural site
Demographics
Age (median, IQR)
N (%) female
N (%) married or de facto
N (%) born in Australia
N (%) observe religion
N (%) Christian
N (%) other religion
Education level (completed)
N (%) not completed secondary
N (%) completed secondary
Primary respiratory diagnosis
N (%) malignant disease*
N (%) COPD
N (%) interstitial fibrosis
N (%) other respiratory
Baseline clinical severity
Eligible for LTOT
MRC dyspnoea (grade 4–5)
Baseline survey measures
Social support (mean, SD)
Care satisfaction (mean, SD)
Health-related quality of life
N (%) mobility symptoms†
N (%) personal care symptoms†
N (%) usual activity symptoms†
N (%) pain and discomfort†
N (%) anxiety and depression†
EQ-5D-5L index (mean, SD)
EQ-5D-5L global VAS (mean, SD)

Usual care
Rand-CON
(N=22)

35 (57%)
26 (43%)

13 (29%)
32 (71%)

5 (23%)
17 (77%)

73 (13)
26 (43%)
28 (46%)
34 (56%)
26 (43%)
23 (88%)
3 (12%)

70 (12.5)
13 (29%)
33 (73%)
25 (56%)
19 (42%)
16 (84%)
3 (16%)

77.5 (8.2)
6 (27%)
16 (73%)
17 (77%)
11 (50%)
8 (73%)
3 (27%)

34 (56%)
27 (44%)

37 (82%)
8 (18%)

17 (28%)
40 (66%)
4 (7%)
–

Pref-CON
(N=21)

Preference
Pref
(N=82)

No Pref
(N=67)

14 (67%)
7 (33%)

49 (60%)
33 (40%)

18 (27%)
49 (73%)

80 (15.5)
10 (48%)
16 (76%)
12 (57%)
11 (52%)
11 (100%)
–

74 (14)
36 (44%)
44 (54%)
46 (56%)
37 (45%)
34 (41%)
3 (4%)

71 (12)
19 (28%)
49 (73%)
42 (63%)
30 (45%)
24 (36%)
6 (9%)

14 (64%)
8 (36%)

8 (38%)
13 (62%)

42 (51%)
40 (49%)

51 (76%)
16 (24%)

13 (29%)
28 (62%)
3 (7%)
1 (2%)

8 (36%)
12 (54%)
1 (4%)
1 (4%)

3 (14%)
15 (71%)
3 (14%)
–

20 (24%)
55 (67%)
7 (8%)
–

21 (31%)
40 (60%)
4 (6%)
2 (3%)

26 (43%)
33 (54%)

11 (24%)
19 (42%)

5 (23%)
11 (50%)

10 (48%)
11 (52%)

36 (44%)
44 (54%)

16 (24%)
30 (45%)

27.9 (5.8)
117 (26.9)

28 (6.2)
114 (31.5)

28.4 (6.8)
116 (29.2)

27.9 (6.9)
128 (39.8)

27.9 (6.0)
120 (30.9)

28.3 (6.3)
115 (30.6)

44 (72%)
34 (56%)
48 (79%)
36 (59%)
29 (48%)
0.43 (0.21)
57.9 (21.5)

26 (58%)
13 (29%)
32 (71%)
20 (44%)
10 (22%)
0.55 (0.24)
64.0 (16.0)

13 (59%)
3 (14%)
14 (64%)
12 (54%)
7 (32%)
0.54 (0.24)
63.4 (20.0)

12
5
14
8
7
0.56
58.3

56 (68%)
39 (48%)
62 (76%)
44 (54%)
36 (44%)
0.46 (0.22)
58.0 (20.5)

39
16
46
32
17
0.54
63.8

(57%)
(24%)
(67%)
(38%)
(33%)
(0.24)
(17.9)

(58%)
(24%)
(69%)
(48%)
(25%)
(0.22)
(17.3)

*Malignant disease includes lung cancer, malignant pleural effusion and mesothelioma.
†Symptoms signal patient self-report of moderate or worse symptoms.
ACP, advance care planning; COPD, chronic obstructive pulmonary disease; EQ-5D-5L, EuroQol 5 Dimensions 5 Level Survey; LTOT,
long-term oxygen therapy; MRC, Medical Research Council; VAS, visual analogue scale.

Among participants assigned to receive the ACP intervention (Pref-ACP or Rand-ACP) with baseline and
3-month follow-up data available (N=82), completion of
ACP discussions about life-sustaining treatments with
loved ones increased from baseline to 3-month follow-up
(62% vs 77%, p<0.05). Among participants assigned to
usual care (Pref-CON or Rand-CON) with baseline and
3-month follow-up data available (N=26), ACP discussions with loved ones showed a trend towards increase
over time (50% vs 73%, p=0.06).
As shown in ﬁgure 2, the rate of self-reported AD completion at 6-month follow-up was higher in the Pref-ACP
group (21/32, 66%) compared with the Rand-ACP
group (7/33, 21%; RR 3.09, 95% CI 1.53 to 6.25,
p<0.001) or compared with those assigned to either
usual care group (1/24, 4%, p<0.001).
6

Factors associated with ACP uptake
Factors associated with completion of different aspects
of ACP are presented in table 5. Baseline ACP discussion
with loved ones was associated with higher social support
(OR=1.1, 95% CI 1.04 to 1.65), while baseline ACP discussion with doctors was associated with lower HRQOL
(OR=0.14, 95% CI 0.03 to 0.64).
Among those assigned to the intervention arm (ie,
Pref-ACP or Rand-ACP), the factors associated with
formal ACP uptake postintervention were the number
of facilitated ACP discussions with the nurse facilitator,
preference for the ACP intervention and baseline eligibility for LTOT. For the same group of participants,
factors associated with informal ACP uptake postintervention included participation in two or more discussions with the nurse facilitator, preference for the ACP
Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415

Downloaded from http://bmjopen.bmj.com/ on May 2, 2017 - Published by group.bmj.com

Open Access
Table 3 Descriptive characteristics of the facilitated ACP intervention
Metropolitan site
N=48 participants
N=32 discussions
Timing of first ACP discussion (% of participants)
N (%) <14 days postconsent
22
N (%) 14–60 days postconsent
7
N (%) >60 days postconsent
2
Number of nurse-led ACP discussions (% of participants)
N (%) no discussions
17
N (%) one discussion
29
N (%) two discussions
2
N (%) three or more discussions
–
People involved in ACP discussion (% of participants)
N (%) with family/carer present once or more
20
Duration of ACP discussions (% of discussions)
N (%) <45 min
7
N (%) 45–90 min
22
N (%) >90 min
2
Location of ACP discussion (% of discussions)
N (%) discussions inpatient setting
2
N (%) discussions outpatient setting
30
N (%) discussions general practice clinic
–
N (%) discussions home visit
–
N (%) discussions telephone call
–

Rural site
N=58 participants
N=109 discussions

(46%)
(15%)
(4%)

58 (100%)
–
–

(35%)
(60%)
(4%)

–
18 (31%)
29 (50%)
11 (19%)

(42%)

21 (36%)

(22%)
(69%)
(6%)

87 (80%)
22 (20%)
–

(6%)
(94%)

8 (7%)
1 (1%)
12 (11%)
65 (60%)
23 (21%)

ACP domains discussed (% of discussions)

Partly

Partly or fully

Partly

Partly or fully

N
N
N
N
N
N
N
N

32
32
32
32
32
32
30
31

31
17
28
31
29
32
25
21

109 (100%)
103 (95%)
109 (100%)
105 (96%)
108 (99%)
103 (94%)
79 (72%)
56 (51%)

84
56
109
64
102
64
44
21

(%) understanding current health state
(%) understanding prognosis
(%) perspective on ‘living well’
(%) understanding future treatments
(%) values and goals of care
(%) wishes for critical care
(%) wishes for “trial of treatment”
(%) cultural, spiritual, religious beliefs

(100%)
(100%)
(100%)
(100%)
(100%)
(100%)
(94%)
(97%)

(97%)
(53%)
(88%)
(97%)
(91%)
(100%)
(78%)
(66%)

(77%)
(51%)
(100%)
(59%)
(94%)
(59%)
(40%)
(19%)

Proportions are calculated ‘by participant’ (number of participants as a proportion of the 106 participants assigned to receive the facilitated
ACP intervention) or ‘by discussion’ (number of discussions as a proportion of the 141 ACP discussions conducted by the nurse ACP
facilitators).
The discussions undertaken by the nurse ACP facilitators as part of the intervention are separate from the outcome measures of ACP
discussions with loved ones and doctors.
ACP, advance care planning.

intervention, more severe shortness of breath, lower
social support and presence of a family member or
carer at one or more of the facilitated ACP
discussions.
DISCUSSION
This study assessed the effectiveness of systematic identiﬁcation of patients with advanced respiratory disease
using a tool modiﬁed from the Gold Standard
Framework to identify those at high risk of death within
12 months,32 and proactive intervention through
nurse-led ACP discussions. The intervention was effective
in increasing formal and informal ACP uptake, particularly among those with a pre-existing preference to
receive the intervention.
The inclusion of a preference arm most likely
increased participation and retention rates, and more
Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415

closely reﬂects real-world situations, in which approaches
to care are negotiated between clinicians and patients.
In practice, there will always be patients who have strong
attitudes about ACP and this trial design enabled recruitment of those who were unwilling to be randomised,
potentially improving generalisability. The nature of the
ACP intervention made it impossible to blind participants to their allocation, and hence a preference design
may have avoided distress among those who wanted a
particular type of care but were not offered it. The preference arm introduces a self-selection bias which should
be considered when interpreting study ﬁndings.44
Facilitated ACP intervention
The ACP intervention differed somewhat across the
study sites due to practical factors. In the metropolitan
setting, the intervention was delivered in outpatient
7
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Table 4 Proportion of participants with formal (completion of formal AD or formal nomination of SDM) or informal ACP
uptake (discussion with doctor about wishes relating to life-sustaining treatment) at baseline and 6-month follow-up
(self-report supplemented by medical notes audit for participants lost to follow-up)
Type of ACP uptake (by condition)
Pref-ACP (N=61)
Formal ACP uptake
Informal ACP uptake
Rand-ACP (N=45)
Formal ACP uptake
Informal ACP uptake
Rand-CON (N=22)
Formal ACP uptake
Informal ACP uptake
Pref-CON (N=21)
Formal ACP uptake
Informal ACP uptake

Baseline
N (%)

Follow-up
N (%)

p Value

1/61 (2%)
25/61 (41%)

42/61 (69%)
50/61 (82%)

<0.001
<0.001

0/45 (0%)
8/45 (26%)

12/45 (27%)
26/45 (58%)

<0.001
<0.001

0/22 (0%)
9/22 (41%)

4/22 (18%)
14/22 (64%)

0.04
0.13

1/21 (5%)
3/21 (14%)

2/21 (10%)
6/21 (29%)

0.55
0.26

ACP, advance care planning; AD, advance directive; SDM, substitute medical decision-maker.

Figure 2 Self-reported
‘readiness’ to complete an
advance directive among
participants assigned to different
study groups over time. The
sample is limited to participants
(N=89) who responded to
baseline, 3-month and 6-month
follow-up surveys.

clinics resulting in barriers to participation, particularly
for participants with signiﬁcant symptoms or mobility
limitations. In the rural setting, the nurse facilitator was
able to visit participants in a range of settings; this
resulted in a tendency for multiple ACP discussions,
often of shorter duration. Previous research has suggested that community-based ACP delivery can accommodate the needs of patients with heavy symptom
burden and enable ongoing ACP discussion.45 However,
in the current study, a lower than anticipated recruitment rate meant that it was not possible to stratify the

8

data in order to assess the impact of the study setting on
the primary outcome.
While the nurses routinely discussed participants’
understanding of their illness, values, goals of care and
perspectives on ‘living well’, discussion about prognosis
and cultural, spiritual or religious beliefs occurred less
often. This may reﬂect participant preferences for
certain domains of discussion, or the nurses’ preferences to avoid aspects of discussion that might be seen
as the traditional domain of doctors or spiritual
advisors.46 47
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Table 5 Final regression models showing factors associated with completion of ACP discussions with loved ones and
doctors at baseline, and factors associated with completion of ACP discussion with doctors, or formal ACP documents
(formal ACP) at follow-up among those assigned to the intervention
ACP domain
Baseline completion of ACP discussion with loved ones (all participants)
Social support (ENRICHD scale)
Education level (completed secondary school)
Baseline completion of ACP discussion with doctors (all participants)
Health related quality of life (EQ-5D-5L index score)
COPD diagnosis
Gender (female vs male)
Postintervention informal ACP uptake (of those assigned to ACP intervention)
(Baseline) social support (ENRICHD scale)
Participation in ≥2 facilitated ACP discussions (vs none)
Family/carer involved in a facilitated ACP discussion (vs not)
(Baseline) MRC shortness of breath grade 4–5 (vs not)
Preferential assignment to ACP intervention (vs random)
Postintervention formal ACP uptake (of those assigned to ACP intervention)
Participation in ≥2 facilitated ACP discussions (vs none)
Participation in one facilitated ACP discussion (vs none)
Preferential assignment to ACP intervention (vs random)
(Baseline) eligibility for LTOT (vs ineligible)

OR

95% CI

1.10
1.84

1.04 to 1.65
0.89 to 3.82

0.14
1.94
1.83

0.03 to 0.64
0.86 to 4.36
0.87 to 3.85

0.85
5.18
4.34
4.25
3.32

0.75 to 0.96
1.07 to 25.1
1.21 to 15.5
1.42 to 12.7
1.18 to 9.33

7.02
4.53
5.81
3.29

1.73 to 35.1
1.12 to 18.3
2.29 to 14.7
1.22 to 8.88

Follow-up completion rates are calculated by supplementing self-report survey measures with follow-up medical notes audit, to include ACP
undertaken by patients who were deceased or otherwise lost to survey follow-up.
ACP, advance care planning; COPD, chronic obstructive pulmonary disease; EQ-5D-5L, EuroQol 5 Dimensions 5 Level Survey; MRC,
Medical Research Council.

ACP uptake and readiness
The facilitated ACP intervention was associated with
higher rates of formal and informal ACP uptake, particularly among those with a strong preference for the intervention, and those who engaged in multiple sessions
with the nurse facilitator. Among those randomly allocated to receive the intervention, uptake was not signiﬁcantly higher than among those assigned to usual care,
suggesting that the intervention was particularly effective
among those with a preference for ACP. However, it
should also be noted that it was rare for patients to be
excluded at the screening stage on the basis of prior
formal AD completion (see ﬁgure 1). This suggests that
a preference for ACP, on its own, does not necessarily
lead to high levels of formal ACP uptake, in the absence
of a facilitating intervention.
Most participants had discussed ACP with loved ones at
baseline, with rates comparable to previous research in a
healthy elderly cohort from the USA.27 Discussion with
loved ones at baseline was associated with social
support,29 48 suggesting that supportive social networks
may enable informal discussions outside of clinical relationships. Discussions with loved ones also increased across
the follow-up period, regardless of assignment to the intervention. This cohort effect may be associated with disease
progression, or may have been prompted by the inclusion
of questions about ‘ACP readiness’ in follow-up surveys.
Consistent with previous research, rates of ACP discussions with doctors were signiﬁcantly lower than completion of formal ACP documents or discussion with loved
ones.27 30 The lower rates of discussion with doctors in
Sinclair C, et al. BMJ Open 2017;7:e013415. doi:10.1136/bmjopen-2016-013415

practice contrast with those studies that suggest that
patients prefer to discuss ACP with their trusted
doctor.20 49 However, this paradox does seem to be overcome somewhat by the nurse facilitation process, as the
rate of informal ACP uptake (documented discussion
with doctor about preferences for life-sustaining treatments) did increase among participants assigned to the
intervention, and was associated with having undertaken
two or more nurse-facilitated ACP discussions. Similarly,
higher rates of ACP discussions with doctors occurred
among participants who had a family/carer involved in
at least one of the facilitated ACP discussions. This
implies that the presence of family/carers in initial ACP
discussions prompts further follow-up with the doctor.
On the other hand, participants with lower social
support were also more likely to have follow-up ACP discussions with doctors, perhaps as these participants are
identiﬁed as potentially vulnerable and hence managed
more proactively. Previous research has found that
patients with more severe symptom burden and lower
levels of social support inﬂuence GP decisions to initiate
ACP discussions.50 Social support is typically lower
among patients with declining health status,51 and
health professionals may need to proactively initiate ACP
discussion among patients whose illness has led to losses
in social support networks. The links between social
support and ACP uptake require further investigation.
Limitations
This study has a number of limitations to consider.
Assignment to study arm was unblinded, and the
9
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preference design introduced a self-selection bias, which
complicates interpretation of the data. There is additional complexity in the interpretation of ACP uptake
over time due to attrition during the follow-up period
(mostly associated with patients dying). This was
addressed where possible by supplementing self-report
measures with information obtained from follow-up
medical notes audits. For measures in which self-report
was the only source of data (eg, ACP discussions with
loved ones), 3 months was designated as the follow-up
point, to minimise the impact of attrition. Where results
are reported longitudinally (eg, ﬁgure 2), the sample is
limited to those who were able to respond at all follow-up
time points. Challenges to recruitment meant that the
overall study sample was smaller than anticipated and
data were collapsed across the two recruitment sites, preventing comparisons across sites. The same nurses who
facilitated the ACP intervention also collected follow-up
survey responses and undertook medical notes audits;
this may be a source of bias. Despite this, high rates of
survey (78% among surviving patients) and notes audit
(98%) completion have yielded detailed data on ACP
uptake among a speciﬁc cohort of patients with advanced
respiratory disease. The authors suggest that the ongoing
relationship between the nurse and participant contributed to the high rates of successful follow-up, and may also
have facilitated high-quality ACP discussions. ACP interventions that occur outside an ongoing clinical relationship may be less effective, and may require more
resources to build patient rapport.
Implications
This study has a number of implications for practice. A
systematic screening process to identify patients with
end-stage lung disease was found to be acceptable to
clinicians and participants, and was sensitive in detecting
patients at high risk of death in the coming year. Many
participants expressed a strong preference to receive the
ACP intervention, suggesting that assessing preference at
the time of screening may enable effective tailoring of
ACP interventions. Assignment to the facilitated ACP
intervention was associated with large increases in ACP
uptake, particularly among those with a pre-existing
strong preference for receiving the intervention, and
those who engaged in multiple sessions, or involved a
family member or carer in the discussion. These ﬁndings suggest that facilitated ACP discussions with trained
nurses are acceptable to patients with advanced respiratory disease, and effective in promoting ACP uptake.6
Programmes aiming to promote ACP uptake may consider assessing patient social support, to identify preferred support people for participation in discussions
and to ﬂag patients who may require more intensive
support in undertaking ACP.
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